<p><strong>纽约，NY / ACCESS Newswire /2025 年 5 月 6 日/</strong> Levi &amp; Korsinsky 通知投资者，已对 Cytokinetics, Incorporated（&#34;Cytokinetics, Incorporated&#34;）展开调查，涉及可能违反联邦证券法的情况。</p>
<p>BioPharma Dive 于 2025 年 5 月 2 日发布了一份关于 Cytokinetics 的报告，指出：&#34;食品和药物管理局已推迟对 Cytokinetics 实验性肥厚性梗阻性心肌病药物 aficamten 的批准决定，以便有更多时间审查该公司提出的风险管理计划。&#34;</p>
<p>在此消息发布后，Cytokinetics 的股票在同一天的下午交易中下跌超过 12%。欲获取更多信息，请访问：</p>
<p>https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=147211&amp;wire=1</p>
<p>或联系 Joseph E. Levi, Esq.</p>
<p><strong>为什么选择 LEVI &amp; KORSINSKY:</strong> 在过去的 20 年里，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼方面拥有丰富的经验，并拥有超过 70 名员工为客户提供服务。连续七年，Levi &amp; Korsinsky 在 ISS Securities Class Action Services 的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。之前的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

细胞动力

<p>Levi & Korsinsky 已对细胞动力公司发起调查，可能涉及违反联邦证券法。这一调查是基于一份报告，该报告指出 FDA 延迟了对细胞动力公司药物 aficamten 的批准，导致该公司股票下跌了 12%。该公司以其在证券诉讼方面的专业知识而闻名，旨在保护投资者的权益</p>

<p><strong>NEW YORK, NY / ACCESS Newswire / May 6, 2025 /</strong> Levi &amp; Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated (&#34;Cytokinetics, Incorporated&#34;)  concerning possible violations of federal securities laws.</p>
<div class="lb-trans"><p><strong>纽约，NY / ACCESS Newswire /2025 年 5 月 6 日/</strong> Levi &amp; Korsinsky 通知投资者，已对 Cytokinetics, Incorporated（&#34;Cytokinetics, Incorporated&#34;）展开调查，涉及可能违反联邦证券法的情况。</p>
</div><p>BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, &#34;The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.&#34;</p>
<div class="lb-trans"><p>BioPharma Dive 于 2025 年 5 月 2 日发布了一份关于 Cytokinetics 的报告，指出：&#34;食品和药物管理局已推迟对 Cytokinetics 实验性肥厚性梗阻性心肌病药物 aficamten 的批准决定，以便有更多时间审查该公司提出的风险管理计划。&#34;</p>
</div><p>Following this news, Cytokinetics' stock dropped over 12% during afternoon trading on that same day. To obtain additional information, go to:</p>
<div class="lb-trans"><p>在此消息发布后，Cytokinetics 的股票在同一天的下午交易中下跌超过 12%。欲获取更多信息，请访问：</p>
</div><p>https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=147211&amp;wire=1</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=147211&amp;wire=1</p>
</div><p>or contact Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>或联系 Joseph E. Levi, Esq.</p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>为什么选择 LEVI &amp; KORSINSKY:</strong> 在过去的 20 年里，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼方面拥有丰富的经验，并拥有超过 70 名员工为客户提供服务。连续七年，Levi &amp; Korsinsky 在 ISS Securities Class Action Services 的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。之前的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

细胞动力公司是否误导了投资者？Levi & Korsinsky 的股东权益倡导者正在进行调查 - CYTK